long intergenic non-protein coding RNA 2295Genealiases: []
Q-omics provides the consensus-scored LINC02295 profile across patient tissues and cancer cell-line models. LINC02295 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LINC02295 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, LINC02295 RNA expression shows 9,614 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, COAD, and THYM as cancer lineages where LINC02295 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02295 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02295 survival associations across molecular data types. LINC02295 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02295 RNA expression–survival associations across cancer types. High LINC02295 expression shows unfavorable associations in STAD, KIRP, COAD and LGG, but favorable associations in OV and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for LINC02295 RNA expression.
This table summarizes LINC02295 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02295. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02295 shows lower tumor expression in COAD and READ and higher tumor expression in LUSC, KIRC and BRCA. The COAD box plot shows higher LINC02295 RNA expression in normal versus tumor tissue (log2 FC = −0.140, t-test p < 0.001).
This table shows molecular features associated with LINC02295 in patient tissues and cancer cell lines. In patient samples, LINC02295 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
